Introduction {#s1}
============

Autophagy is derived from a Greek word (αυτοϕαγϵἷν) meaning 'self-eating' and is a bulk degradation process, which includes the lysosomal-dependent degradation and recycling of components of eukaryotic cells. It has essential roles in keeping the cellular homeostasis and functions in cellular differentiation, control of cellular growth, cell defense, and promotes tissue remodeling and acclimatization. Autophagy either can have a protective function for cell survival or promote cell death. Alkylphosphocholines (APCs) are phospholipid-derived agents that cause changes in cell signaling by enriching in cell membranes including the lipid rafts. This physicochemical property and the resultant changes are basis for their anticancer, antiprotozoal, antibacterial, and antiviral activities. They induce autophagy as part of their mechanism of action. This review summarizes the current knowledge on alkylphosphocholines (APCs) regarding their influence on autophagy. It covers the following topics: Types of autophagy, role of autophagy in cancer, autophagy as a therapeutic target, APCs (miltefosine, perifosine, and erufosine) in general, as modulators of autophagy, and conclusion.

Types of Autophagy {#s2}
==================

Four types of autophagy have been recognized based on the nature of their cargo, their cargo size, and degradation rate, *i.e.* chaperone mediated autophagy (CMA), microautophagy, macroautophagy, and selective autophagy ([@B56]; [@B14]; [@B87]; [@B90]; [@B13]). The lysosomal degradation of damaged proteins is common to all the previously mentioned types of autophagy, but the mechanism of delivering the substrate to the lysosome varies among the different types ([@B13]). The following part gives a short description of these four types.

Chaperone Mediated Autophagy {#s2_1}
----------------------------

Chaperone proteins recognize substrate proteins for chaperone mediated autophagy (CMA, see [**Figure 1A**](#f1){ref-type="fig"}) by the penta-peptide motif KFERQ (*i.e.* K: lysine--F: phenylalanine--E: glutamic or aspartic acid--R: arginine--Q: glutamine) ([@B61]; [@B13]). Together with their chaperones, these proteins will be transported to lysosomes for breakdown in a receptor dependent manner ([@B14]). The native state of a substrate protein usually hides the recognition motif within the protein core, but it comes to be accessible by its respective chaperone regardless of its location within the protein. Examples for chaperones include heat shock cognate protein of 70 kD (Hsp70) and cochaperones as Hsp90, Hsp40, and Bcl-2-associated athanogene 1 (Bag-1). The latter will unfold the proteins before substrate--chaperone interactions can occur, eventually even without direct interaction. Then, the substrate is transferred to the lysosomal lumen after binding to the cytosolic tail of lysosome-associated membrane protein type 2A (LAMP-2A), which multimerizes to that purpose ([@B1]; [@B11]; [@B14]; [@B61]). CMA activity is directly proportional to the level of LAMP2A in the lysosomal membrane. CMA consists of four stages: recognition of the substrate, substrate binding, substrate translocation, which is an ATP dependent step, and finally substrate hydrolysis within the lysosome by proteolytic enzymes ([@B30]). Hsp90 maintains the stability of LAMP2A receptor during multimerization ([@B30]). Starvation of more than 10 h, oxidative stress, and exposure to toxic compounds will induce CMA. Under such conditions, the level of LAMP2A increases to meet the requirement of increasing CMA, and this occurs through degradation of the LAMP2A complex and transferal of its constituent proteins to the lysosomal membrane ([@B13]). The levels of LAMP2A protein are clearly organized by degradation at the lysosomal membrane, distribution between this structure and its lumen, or by *de novo* synthesis ([@B74]). The interaction of substrate and chaperone to form a complex is considered the rate-limiting step of the CMA process ([@B74]). However, the by age abridged stability of LAMP2A reduces CMA, which initially can be compensated by increased lysosome numbers ([@B74]; [@B13]). Reduced CMA activity as age-related effect results mainly in deficient binding and uptake of substrates into the lysosomal membrane, while kinetics of degradation is comparable to younger ages. The reduced CMA activity may have a role in the accumulation of altered products observed with aging ([@B74]).

![Types of autophagy: The four types of autophagy include chaperone mediated autophagy, microautophagy, selective autophagy, and macroautophagy. **(A)** Chaperone-mediated autophagy involves the recognition of a KFERQ penta-peptide motif in substrate proteins by corresponding chaperone proteins. The substrate is then transferred to the lysosomal lumen after binding to the LAMP protein. **(B)** Microautophagy is the process of sequestering minute parts of the cytoplasm and their engulfment by lysosomal invagination. **(C)** During selective autophagy, the respective cargo (*e.g.* invading pathogens, damaged mitochondria, or others) is specifically bound by autophagy receptors. The autophagy receptor has the ability to bind LC3 proteins through its LC3 interacting region (LIR) on the autophagosome beside binding molecular determinants, such as unfolded regions of a protein or conjugated ubiquitin (Ub) through its ubiquitin binding domain (UBD). **(D)** Macroautophagy consists of several steps of nucleation, elongation, maturation, and finally fusion and degradation. The process starts by the association of the ULK1 and BECN1 complexes that form the basis for recruiting other autophagy-related (ATG) proteins as well as the lipidated form of LC3 (LC3-II, *i.e.* LC3-I linked to phosphatidyl-ethanolamine). The ULK1 complex consists of the serine/threonine kinase UNC-51-like autophagy activating kinase (ULK1), focal adhesion kinase family interacting protein of 200 kDa (FIP200), ATG13, and ATG101. The PI3 kinase III nucleation complex (BECN1 complex) consists of Beclin-1, class III phosphoinositide 3-kinase \[PI3K-III; also termed vacuolar protein sorting 34 (VPS34)\] and its regulatory subunit VPS15. LC3-I protein is formed from its precursor protein, pro-LC3 with the contribution of ATG4. After attaching phosphatidyl-ethanolamine (PE) to LC3-I by ATG7 and ATG3, the lipophilic form (LC3-II) is created. The closed autophagosome fuses with a lysosome to form the autolysosome, where the proteins undergo degradation by different lysosomal enzymes.](fphar-11-00547-g001){#f1}

Microautophagy {#s2_2}
--------------

Microautophagy denotes the process of sequestering tiny parts of the cytoplasm and their subsequent engulfment through lysosomal invagination as shown in [**Figure 1B**](#f1){ref-type="fig"} ([@B103]).

Five phases of microautophagy have been identified: the first phase is the microautophagic invagination and formation of autophagic tubes, where the normal membrane bulges by lateral seclusion of lipids and local segregation of large transmembrane proteins toward the surface of lysosomes or vacuoles, and by an ATP dependent process then forms an autophagic tube. The second phase is vesicle formation, which is the equivalent of autophagosome formation in macroautophagy. It occurs because of the lateral organizing mechanism, where autophagic tubes invaginate because high-density lipids combine with low-density proteins. Vesicle expansion is the third step, which is characterized by the hanging of a prevesicular structure that dynamically moves back and forth in the lysosomal/vacuolar lumen. The formed vesicle does not contain proteins but lipids of high density because of the mechanism of lateral sorting. Finally, vesicle scission occurs because of the dynamic trend, where one or two vesicles bud into the lumen of the lysosome and move freely at high speed. Vesicle degradation happens because of the effect of some hydrolases that break down the freely moving vesicles. Recycling of the nutrients is done by a permease like action of ATG22p ([@B87]).

Selective Autophagy {#s2_3}
-------------------

As compared to macroautophagy, which is considered nonselective, selective autophagy ([**Figure 1C**](#f1){ref-type="fig"}) ensures recognition and elimination of specific cytosolic cargoes. Selective autophagy is specific for its substrates *e.g.*, for damaged mitochondria (mitophagy), aggregated lipids (lipophagy), invading pathogens (xenophagy), or excess peroxisomes (pexophagy); these specific cargoes undergo degradation after being identified by autophagy receptors and are encircled into a double-membrane vesicle, the autophagosome, and transported to the lysosome for further breakdown ([@B124]). The specificity is determined by identification of selective autophagy receptors ([@B124]), which have the ability to bind LC3/GABARAP proteins on the forming autophagosome in addition to binding molecular elements, such as unfolded regions of a protein or conjugated ubiquitin (Ub). Then, through self-oligomerization, they contribute to the association of specific platforms on which autophagosomes form. Among the autophagy receptors are p62/sequestosome 1 (p62/SQSTM1), optineurin (OPTN), neighbor of BRCA1 (NBR1), and nuclear dot protein 52 kDa (NDP52). All of them possess a ubiqitin-binding domain (UBD) and LC3-interacting regions (LIRs) ([@B124]; [@B132]; [@B31]; [@B13]).

Macroautophagy {#s2_4}
--------------

Macroautophagy (see [**Figure 1D**](#f1){ref-type="fig"}, will be referred later as autophagy) involves the formation of isolation membranes (IMs), which extend as they ingest parts of the cytoplasm and organelles to produce autophagosomes ([@B53]). This whole process is nonselective ([@B13]). Autophagosomes are double membrane structures, which function in delivering cargos to lysosomes or endosomes ([@B37]). Autophagy is a complex mechanism with the involvement of several autophagy related proteins. Autophagy related proteins (ATG) responsible of the autophagy process were essentially discovered from yeast genome ([@B76]; [@B37]). The source of the autophagosomal membrane is uncertain, as it is discussed to originate from endoplasmic reticulum (ER), mitochondria, or plasma membranes ([@B138]; [@B53]; [@B107]; [@B144]). Hailey and coworkers found that the external membrane of the mitochondria adds to autophagosome production in fasting cells ([@B52]). Both the endoplasmic reticulum (ER) and the early autophagic structures of IMs are interconnected. Electron tomography showed that the ER--IM complex is a subdomain of the ER that forms a frame surrounding the IM ([@B56]). Other studies suggested' that autophagosomes form at the ER--mitochondria contact site in mammalian cells ([@B53]), or that the plasma membrane serves as a reservoir and participates openly in the development of positive autophagosome precursors during periods of increased autophagosome formation ([@B121]). Furthermore, studying the intracellular dynamics of ATG9 in yeast showed that the Golgi apparatus derived ATG9 vesicles incorporate into the autophagosomal outer membrane at the initial stages of autophagosome generation ([@B148]). Recycling endosomes represent membrane platforms that contribute to the formation of phagophores ([@B117]).

### Mechanism and Regulation of Autophagy {#s2_4_1}

Autophagy constitutes of several sequential steps, namely initiation or nucleation, phagophore elongation, autophagosome maturation, autophagosome fusion with the lysosome, and proteolytic degradation of the contents ([@B73]). The initial step usually begins with the association of the initiation complex (ULK1 complex). This complex consists of ULK1 (UNC-51-like autophagy activating kinase, a serine/threonine kinase), FIP200 (focal adhesion kinase family interacting protein of 200 kDa), ATG13 and ATG101, together with the nucleation complex (BECN1 complex) consisting of Beclin-1, class III phosphoinositide 3-kinase \[PI3K-III or vacuolar protein sorting 34 (VPS34)\] and its regulatory subunit VPS15. The latter represent the platform for recruiting other ATG proteins and for elongating the phagophore membrane ([@B90]; [@B13]).

The three proteins VPS34, VPS15, and BECN1 make up the core, induce the elevated phosphatidylinositol 3-phosphate (PI3P) level of autophagic membranes, and can form, together with a fourth subunit, two different complexes. When this subunit is the UV radiation resistance associated (UVRAG) protein, the complex plays an essential role in endosomal maturation, but when the complex harbors ATG14L, it is required for autophagy. Engaging the BECN1 core complex to the phagophore assembly site (PAS) requires the function of ATG14L. Lipidation of ATG8/LC3 with phosphatidyl-ethanolamine (PE) is a crucial step in elongating the phagophore. Two ubiquitin-like conjugation systems act on this, namely: ATG7 with its E1 enzyme-like protein stimulating activity and ATG10 with its E2 conjugation enzyme like function. Their activities result into covalent bonding between ATG12 and ATG5. A multimeric complex, made of ATG5-ATG12 and ATG16L1, functions as a ubiquitin ligase like enzyme and facilitates binding of ATG8/LC3 to PE. Prerequisite to this step, LC3-I protein is formed by processing its precursor protein pro-LC3 with the protease ATG4. Then ATG7 and ATG3 activate ATG8 by E1 and E2 like enzymatic actions, and as a result, the lipophilic form (LC3-II) is created and bound to both membrane leaflets of the phagophore ([@B90]). LC3-II can be considered as the best marker of autophagy, as its concentration is directly proportional to the number of autophagosomes formed ([@B25]) ([@B13]). All ATGs, with the exception of ATG8/LC3, dissociate from the membrane before closure and are recycled. Recycling of ATG8/LC3 occurs after closure of the autophagosome with the help of ATG4, while lysosomal enzymes in the autophagosome lumen cleave the proteins attached to the internal membrane ([@B90]). Autophagosomes bind to late endosomes and lysosomes to form the autolysosomes and proceed for degradation ([@B90]). LAMP proteins regulate the fusion and prevent degradation of the lysosomal membrane ([@B59]; [@B90]). The merger of the autophagosome with the lysosome to result in the autolysosome is facilitated by either the soluble NSF (N-ethylmaleimide sensitive factor) attachment protein (SNAP) receptor (SNARE) protein complex, or UVRAG, but many players can be involved in this process including cytoskeleton constituents and associated motor proteins, tethering factors, phospholipids, and specific SNARE complexes. This step is finished by degrading the interior autophagosomal membrane by lysosomal enzymes ([@B13]; [@B154]). [**Figure 1D**](#f1){ref-type="fig"} shows the follow-up of steps described for macroautophagy.

Autophagy as a process is highly conserved and firmly controlled in mammals. The most important physiological regulator of autophagy is the availability of nutrients and amino acids. Other regulators include mTOR, especially its complex 1 (mTORC1), and inhibition of mTORC1 results in autophagy induction. In addition, starvation and amino acid depletion result into autophagy induction. This usually happens through activating adenosine monophosphate-activated protein kinase (AMPK), which transfers a phosphate group to ULK1, or by impeding mTORC1 activity, or through inhibitory phosphorylation of nonautophagic BECN1 complexes. Other autophagy regulators depend on an increase in cytosolic calcium, inhibition of inositol triphosphate or starvation induced autophagy ([@B113]; [@B37]; [@B64]; [@B90]). Furthermore, oxidative stress ([@B42]), DNA damage ([@B49]) as well as hypoxia ([@B40]) can all induce autophagy. Activation of class I PI3-kinases inhibits autophagy, while class III PI3-kinase activity is required for autophagosome formation.

Autophagy breaks macromolecules and then provides nutrients and functions as a survival mechanism during short-term starvation ([@B37]; [@B90]). It eliminates damaged proteins and organelles and helps in the organelle turnover. It fights against attacking pathogens and in general preserves the cellular homeostasis and balance ([@B37]; [@B90]).

Autophagy also results into type II programmed cell death and is related to apoptosis in several ways. The tumor suppressor death-associated protein kinase (DAPk) may contribute to the signaling pathway linking autophagy to cell death. Certain types of cell death depend on autophagy proteins for the execution of cell death. Autophagy can protect cells from the apoptotic fate by providing nutrients, especially under conditions of starvation. The regulation of both processes is related to the pro-survival protein Bcl-2. Bcl-2 binds to Beclin 1 and prevents its interaction with VPS34. Thus, it inhibits the Beclin 1 dependent autophagy and maintains autophagy at levels harmonious with cell survival, rather than cell death ([@B37]; [@B13]).

Different human diseases are associated with deregulation of autophagy, including neurodegenerative diseases and proteinopathies, lysosomal disorders, many cardiovascular diseases, cancer, diabetes and immune disorders. Infections and pathogens control autophagy based on their needs to assure their persistence in host cells ([@B90]).

### mTOR Regulation of Autophagy {#s2_4_2}

Autophagy is controlled by a negative feedback mechanism of the mTOR pathway and modulators of this pathway have an impact on and can regulate autophagy ([@B66]; [@B75]). In normal cellular states and when amino acids are abundant, mTORC1 binds to the ULK complex by interaction of its component RAPTOR with ULK1. Then, mTOR transfers phosphate groups to ULK1 (specifically at its S757 and S637 residues) and ATG13 and thus hinders the ULK1 kinase activity. Under fasting conditions, the mTOR regulatory pathway is inhibited, and this leads to induction of autophagy because mTORC1 separates from the ULK complex and therefore its inhibitory control on ULK1 is gone, which allows autophagy to proceed ([@B118]). LKB1, AMPK, TSC1/TSC2 complex, and PTEN in mTOR signaling pathways can induce autophagy, while Akt and Rheb have an inhibitory effect. mTOR is inhibited at the beginning of autophagy and becomes activated later on, due to the release of breakdown molecules in the cytoplasm, which result into inhibition of the whole process. Enlarged mTOR activity then impedes autophagy and induces the formation of proto-lysosomal extensions (LAMP1+, LC3−) from autolysosomes (LAMP1+, LC3+). Finally, these proto-lysosomal extensions separate from the autolysosome and advance into functional lysosomes. Impediment of mTOR or its (auto-) lysosomal activity precludes autophagic lysosome restoration ([@B71]).

Role of Autophagy In Cancer {#s3}
===========================

In carcinogenesis, the role of autophagy is controversial with many conflicting reports in the literature. Autophagy can either impede or favor cancer development and progression, which depends on the wild-type or transformed state of the cell, the underlying genetic lesion(s), the tumor type and stage, as well as the tumor microenvironment ([@B44]; [@B108]; [@B13]; [@B73]).

Under normal conditions, autophagy acts as a protector against cancer development. In contrast, during stress situations, autophagy helps cells to adapt against hypoxia and nutrient deficiency and can save cancer cells from death ([@B44]; [@B108]; [@B13]). Fighting mutagenic effects (*e.g.* DNA damage or instability of the genome) occurring from accumulation of reactive oxygen species (ROS) and degrading of oncogenic proteins are among the protective functions that autophagy can exert to inhibit cancer induction ([@B44]; [@B108]; [@B13]). A reduced level of autophagy will hinder the ability of the cells to eliminate impaired proteins and damaged organelles and hence begin to mount up cytotoxic components that can cause damage to DNA and initiate carcinogenesis ([@B13]). Autophagy can suppress tumorigenesis through cell cycle and cell death regulation in conjunction with the ubiquitin--proteasome system (UPS), which can modify some key cell cycle components of CDK-Cyclin complexes ([@B73]).

Autophagy is required for immune activation as it plays a role in antigen presentation to T lymphocytes. It helps the maturation of some innate immune cells when activated and contributes to their antitumor activity. It can play a role in combatting cancer through activation of the immune system ([@B62]). Nevertheless, hypoxia-induced autophagy may result in the activation of immune escape mechanisms in the tumor microenvironment ([@B62]). Regarding the anticancer effects, some autophagic genes and inducers are mutated or deleted in certain cancers, as p53 and PTEN (phosphatase and tensin homolog), which are the most frequently altered tumor suppressor genes, and Beclin-1 (BECN1), which is deleted in breast and ovarian cancers ([@B13]).

Regarding the tumor supportive roles, autophagy provides tumor cells access to nutrients that are crucial to their metabolism, promotes DNA repair, reduces mitochondrial disorders, and increases drug resistance ([@B25]; [@B13]). Autophagy also helps tumor cells to resist stress and apoptotic signals; it provides cells with energy through increasing ATP concentrations that favor cell survival during hypoxia and starvation. Autophagy is linked in late cancer to poor prognosis and invasiveness ([@B44]; [@B108]) and favors tumor growth through rendering cells more resistant to apoptotic signals and stress stimuli as well as resistance to therapy induced cell death. Furthermore, autophagy maintains the neoplastic stem cell compartment and epithelial-to-mesenchymal transition (EMT) ([@B44]).

In metastasis, autophagy can also play a dual role, based on the stage. In early stages, autophagy may stimulate inflammatory responses and limit tumor necrosis. Further, autophagy may limit the development of dormant cancer cells into micrometastases, as well as prevent oncogene induced senescence. However, in advanced stages, autophagy tends to increase the life span of circulating metastatic cells, which lack an extracellular matrix, by inducing dormancy in the new environment until favorable conditions occur ([@B25]).

In this context, the autophagosome marker LC3B showed moderate to high expression in solid cancers, as breast cancer and melanomas, and its expression is linked to cell growth, invasion and metastasis, high tumor grade, and poor prognosis ([@B82]).

To summarize, autophagy protects against malignant transformation under normal conditions by maintaining the cellular homeostasis, but increases tumor progression and invasiveness after tumor establishment ([@B44]; [@B108]). The different roles of autophagy in cancer are shown in [**Table 1**](#T1){ref-type="table"}.

###### 

The dual role of autophagy in cancer^a)^.

  Onco-stimulatory roles                                                             Onco-suppressive roles
  ---------------------------------------------------------------------------------- -----------------------------------------------------
  Support of cancer stem cells                                                       Clearance of intracellular pathogens
  Providing cells with an alternative energy source                                  Favoring the genomic stability
  Inhibition of cell death                                                           Reduction of DNA damage and reactive oxygen species
  Reduction of cellular sensitivity to stress stimuli                                Reduction of inflammation
  Maintaining the dormancy state of tumor cells until favorable conditions are met   Stimulation of autophagic cell death
  Promotion of drug resistance                                                       Removal of damaged organelles and proteins

^a)^modified from ([@B25]; [@B13]).

Aspects of Autophagy in Disease Prevention {#s3_1}
------------------------------------------

The physiologic functions of selective autophagy recently have been perceived as potentially preventive measures. Basis for this concept is *e.g.* the observation that aging mammalian cells accumulate dysfunctional mitochondria, which can be eliminated by selective autophagy ([@B54]). Mitophagy, *i.e.* the elimination of aged mitochondria is therefore a concept of antiaging strategies as well as for diseases that are characterized by a pathophysiology, which is related to mitochondrial disorders, including heart disease, retinopathy, and a series of neurodegenerative sicknesses as *e.g.* Alzheimer's disease. Tolerable induction of mitophagy could thus pave the way to neuroprotection and healthy longevity ([@B39]; [@B93]). Calorie restriction, low insulin/IGF1 levels, and the intake of NAD+ precursors are examples of a strategy aiming to increase the clearance of damaged mitochondria. NAD+ is a cofactor of the NAD-dependent deacetylase sirtuin-1, which can induce mitophagy ([@B84]). Sirtuin activating compounds include resveratrol, which together with NAD+ precursors (tryptophan, nicotinic acid, nicotinamide, nicotinamide mononucleotide, and nicotinamide riboside) could be basis of a dietary approach to healthy longevity ([@B22]).

Autophagy as Therapeutic Target {#s4}
===============================

Autophagy maintains the intracellular metabolic homeostasis, and its dysfunction is associated with numerous diseases including cancer, neurodegeneration, cardiac ischemia, metabolic dysfunctions, infections, autoimmune and pulmonary disorders. Aging and associated atherosclerotic cardiovascular diseases may be slowed down by increasing autophagic flux through calorie restriction, fasting, exercise, and nutritional support such as with spermidine-rich food ([@B95]). Autophagy is also being considered as a "druggable" process due to its fine regulation by diverse signaling pathways, hence involvement of multiple targets ([@B45]; [@B105]). Whether pharmacological modulation of autophagy may be advantageous over life-style interventions remains an open question ([@B95]).

Autophagy as a therapeutic target in cancer is a double-edged sword, which can both enhance neoplastic growth or suppress cancer cell survival. Cancer cells can adapt to hyponutrient conditions and protect themselves against cancer chemotherapeutics by increasing autophagic flux ([@B151]). At the same time, induction of autophagy enables antigen cross-presentation, which stimulates antitumor immune response and may protect against relapses ([@B95]). On the other hand, autophagy contributes to multidrug resistance (MDR) development. Autophagy inhibitors or silencing of ATGs by microRNAs can thus sensitize cancer cells to chemotherapy, enable the use of lower dosage, and reduce adverse effects. However, autophagy inducers may also reverse MDR and sensitize apoptosis-resistant MDR cells to cancer chemotherapeutics ([@B89]).

Deregulated autophagy can be modulated by either inhibiting or inducing identified targets in relevant pathways. Preclinical data followed by clinical trials demonstrate that some old drugs with already well-known safety profiles may be beneficial as autophagy modulators in certain diseases. Among these "conventional" drugs, metformin, the drug of choice in type 2 diabetes mellitus, is also being recognized as an antiaging agent because of its autophagy enhancing effect. In addition, antimalarial drugs have gained attention as autophagy inhibitors, including chloroquine (CQ) and hydroxychloroquine (HCQ). They are the mostly investigated drugs for this purpose in clinical studies, especially in cancer. Other autophagy inducers like mTOR inhibitors, BH3 mimetics, the receptor tyrosine kinase inhibitor sorafenib, the proteasome inhibitor bortezomib, the antigout agent colchicine, the nonreducing disaccharide trehalose, and 2-deoxyglucose have entered clinical phase trials against cancer and neurodegenerative diseases.

Many novel autophagy modulators were evaluated in preclinical trials, but only some of these molecules have succeeded to pass the clinical development phase, and most of the phase trials were based on repurposing of old drugs. Macroautophagy modulators, which have entered phase I--III trials and their mechanisms of action are illustrated in [**Figure 2**](#f2){ref-type="fig"}. The key inhibitor of autophagy, mTORC, can be inhibited by AKT-inhibitors (alkylphosphocholines, see below) and mTOR-inhibitors (sirolimus, everolimus, temsirolimus, sorafenib, metformin, and vorinostat), and by adenosine monophosphate-activated protein kinase (AMPK) activation (devimistat, metformin and trehalose). The other two autophagy targets in the downstream pathway are ULK1 and BECLIN1, which can be activated by ULK1 activator/BECLIN1 releasers such as sorafenib, trehalose, gossypol and BH3 mimetics (BCL-2 inhibitors like obatoclax). Sorafenib and bortezomib can also induce ATG activation. Autophagic flux can be enhanced by endoplasmic reticulum stress and related unfolded protein response (UPR) signaling (alkylphosphocholines, sorafenib, 2-deoxyglucose), inhibition of glycolysis (2-deoxyglucose) and blockade of the cargo receptor p62/sequestome1 (p62/SQSTM1) degradation (bortezomib). The histone deacetylase 6 (HDAC6) inhibitor ricolinostat, lysosomal acidification inhibitors (CQ, HCQ), proton pump inhibitors (pantoprazole) and the autophagosome--lysosome fusion inhibitor trehalose can inhibit autophagosome maturation and autophagolysosomal degradation. The detailed mechanisms of actions of these autophagy modulators are given in [**Table 2**](#T2){ref-type="table"}.

![Modulators of autophagy Inhibitors of autophagy include Akt-inhibitors (alkylphosphocholines, MK-2206, curcumin, quercetin); AMPK activators (metformin, trehalose, 2-deoxyglucose, devimistat); ERK activators (bortezomib); mTOR-inhibitors (sirolimus, temsirolimus, sorafenib, metformin, vorinostat); mTOR-assembly inhibitors (alkylphosphocholines); ULK1 activators/Beclin releasers (sorafenib, trehalose); BH3-mimetics/BCL-2 inhibitors (obatoclax, gossypol); acetylators/deacetylators/activators of autophagy related (ATG) proteins (spermidine, sorafenib, bortezomib); upregulators of LC3; TFEB/p62 (colchicine, bortezomib); inhibitors of lysosomal acidification (chloroquine, hydroxychloroquine); proton pump inhibitors (pantoprazol), and inhibitors of the fusion of lysosomes with autophagosomes (trehalose).](fphar-11-00547-g002){#f2}

###### 

Autophagy modulators in clinical trials and their mechanisms of action.

  Modulator                                            Modulation               Mechanism of Action                                                                                                                                                                                                                          Reference
  ---------------------------------------------------- ------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------
  HCQ and CQ                                           Inhibition               Inhibition of lysosomal acidification and thus the blockade of the terminal step of autophagic substrate degradation                                                                                                                         ([@B112])
  Rapamycin (sirolimus) Everolimus Temsirolimus        Activation               mTOR inhibition.                                                                                                                                                                                                                             ([@B97])
  Pantoprazole                                         Inhibition               Inhibition of H+/K + ATPase proton pumps in membranes of intracellular endosomes and increase of endosomal pH, resulting in inhibition of autophagosome maturation.                                                                          ([@B101])
  Metformin                                            Activation               Activation of AMPK, a sensor of cellular energy levels (increased AMP/ATP ratio) in the cell                                                                                                                                                 ([@B109])
  Ricolinostat (ACY-1215)                              Inhibition               Selective inhibition of HDAC6, which mediates trafficking of ubiquitinated misfolded proteins to the aggresome/autophagy pathway.                                                                                                            ([@B142])
  Vorinostat (suberoylanilide hydroxamic acid; SAHA)   Activation               Pan-HDAC inhibitor; inhibition of mTOR, which results in the dephosphorylation, and thus activation, of the autophagic protein kinase ULK1 and increases LC3 expression.                                                                     ([@B46])
  Devimistat (CPI-613)                                 Inhibition               Inhibition of pyruvate dehydrogenase and ketoglutarate dehydrogenase of TCA cycle, thus impairment of pancreatic cell mitochondrial metabolism.                                                                                              ([@B115])
  Spermidine                                           Activation               Suppression of acetyltransferase activity of EP300, and inducing the acetylation or deacetylation of autophagy-related genes (Atgs).                                                                                                         ([@B149])
  Bortezomib                                           Inhibition; activation   Induction of ERK phosphorylation to suppress cathepsin B, thus inhibition of the catalytic process of autophagy; blockade of p62 degradation.Induction of autophagy through endoplasmic reticulum stress.                                    ([@B69])([@B88])
  Sorafenib                                            Activation               Activation of HP1-STAT3-Mcl-1-Beclin1 pathway and releasing Beclin1 from Mcl-1; mTORC1 inhibition; activation of IRE1 signaling pathway of ER stress, thus reduction of ER stress-induced cell death; activation of AMPK.                    ([@B135])
  Colchicine                                           Activation               Upregulation of proteins involved in autophagy, including the master regulator transcription factor EB (TFEB), the TFEB regulated adaptor protein SQSTM1/p62 and autophagy player microtubule-associated protein 1A/1B-light chain 3 (LC3)   ([@B98])
  ^188^Re-liposome                                     Inhibition               Microtubule-associated protein 1 light chain 3B (LC3) and lysosomal proteins, including Lamp-1 and cathepsin-B and p21WAF/Cip1 levels decline. 188Re-liposome is effective in the suppression of stemness markers' expression.               ([@B26])
  Trehalose                                            Inhibition; activation   Inhibition of autophagosome and lysosome fusion.Inhibition of cellular import of glucose and fructose through SLC2A (GLUT) transporters; stimulation of autophagy through AMPK and activation of ULK1.                                       ([@B83])([@B100])
  NAD+ (and its precursors)                            Activation               Induction of autophagy/mitophagy                                                                                                                                                                                                             ([@B22])
  2-deoxyglucose                                       Activation               ER stress and unfolded protein response; inhibition of glycolysis.                                                                                                                                                                           ([@B131])

AMPK, 5′ AMP-activated protein kinase; HDAC, histone deacetylase; TCA cycle, tricarboxylic acid cycle; TFEB, master regulator transcription factor EB; SQSTM1/p62, the TFEB regulated adaptor protein; microtubule-associated protein 1A/1B-light chain 3; ER, endoplasmic reticulum, NAD+, nicotinamide adenine nucleotide.

Clinical Development {#s4_1}
--------------------

Today, published clinical data have demonstrated sufficient evidence for efficacy in various disorders. They also indicate the need for further studies, which is expected to open a new era of autophagy-based therapies. Published clinical trials with or without (only protocol) results are summarized in [**Tables 3**](#T3){ref-type="table"} and [**4**](#T4){ref-type="table"}. These studies were searched in the PubMed data base using the key words "phase I/II/III trial OR clinical study" AND "autophagy" ([**Tables 3**](#T3){ref-type="table"} and [**4**](#T4){ref-type="table"}) or they were included in the tables following searching in the NCT data base using the key words "autophagy" AND "drug/intervention". Registered clinical trials listed in the NCT database are summarized in [**Table 5**](#T5){ref-type="table"}. Most of these clinical studies focus on cancer, but new fields such as infections, neurodegenerative diseases, antiaging, cognitive decline, venous endothelial function, and inflammation reduction in acute coronary syndrome are also under investigation.

###### 

Published clinical trials based on autophagy modulation in neurodegenerative, infectious, and other diseases.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study Design/Registry Number                 Regimen                                                        Indication/Autophagy Biomarker                                                                                                                                                                                                                                             Indication/Aims--Results/Status                                                                                                                                                                                                                                                        Reference
  -------------------------------------------- -------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------
  Phase II\                                    Colchicine\                                                    ALS/Quantification of mRNA and protein levels of p62, LC3, TFEB, ATGs, HSPB8, BAG3, BAG1, HSP70 and HSF1 in PBMCs, lymphoblasts and fibroblasts (transcriptome profile)                                                                                                    Efficacy of colchicine on disease progression as measured by ALS Functional Rating Scale - Revised (ALSFRS-R) at baseline and at treatment end. Results are not yet available.                                                                                                         ([@B98])
  R, DB, PC, MC\                               0.01 mg/kg/d; 0.005 mg/kg/d\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  NCT03693781\                                 Riluzole: 100 mg/d\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Eudract n.2017-004459-21                     Treatment: 30 wt\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                               Follow-up: 24w                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Phase II\                                    Sirolimus\                                                     ALS/mTOR downstream pathway (S6RP phosphorylation)                                                                                                                                                                                                                         Efficacy of sirolimus in ALS patients on functional rating scale, survival, forced vital capacity, and quality of life. Results are not yet available.                                                                                                                                 ([@B97])
  R, DB, PC, MC\                               1  mg/m^2^/d; 2  mg/m^2^/d                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Eudract n.2016-002399-28                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Case report, OL, R\                          1,000--1,500 mg metformin plus insulin and anti-TB treatment   Diabetes mellitus and tuberculosis/MAP1LC3B                                                                                                                                                                                                                                MET has the potential to enhance the bactericidal effect of antituberculosis (sputum smear reversion after 2 months) *via* autophagy. MAP1LC3B level increased significantly by metformin treatment.                                                                                   ([@B109])
  N (Test) = 22\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  N (control) = 20                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Phase IIa, R, PC, double blind NCT03094546   Spermidine-based nutritional supplementation                   Elderly with subjective cognitive decline/LC3 I/II, p62, EP300, proteomics, metabolomics, polyamine levels, metabolomics, proinflammatory biomarkers, and neurotrophin levels                                                                                              Results are not yet available.                                                                                                                                                                                                                                                         ([@B146])

  Phase IIB, OL, RCT\                          İsoniazid: 150--300 mg/d\                                      Newly diagnosed smear positive pulmonary tuberculosis/immunological and autophagy biomarkers (T cell, monocyte and dendritic cell functions ESAT-6/CFP-10, Culture filtrate Protein, estimation of C reactive protein, tumor necrosis factor-alpha and other cytokines).   Autophagy response will be evaluated as a secondary endpoint. Results are not yet available.                                                                                                                                                                                           ([@B110])
  CTRI/2018/01/011176                          Rifampicin. 300--600 mg/d\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                               Pyrazinamide: 800--1,600 mg/d\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
                                               Ethambutol: 550--1,100 mg/d\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                               Test group: plus metformin 1,000 mg/d                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Phase IIa, R, PC, double blind NCT02755246   Spermidine-rich plant extract supplement                       Behavioral mnemonic similarity task/not assessed                                                                                                                                                                                                                           Memory performance was moderately enhanced and mnemonic discrimination ability improved in the treatment group versus the placebo group/not assessed                                                                                                                                   ([@B145])

  Phase IV, R, quadruple-blind\                CQ: 150 mg/d × 8 + 4 w\                                        HCV/HCV genotype, IL28 genetic polymorphism                                                                                                                                                                                                                                A significant decrease in HCV-RNA after the treatments (week 8) was observed in all patients in the CQ-group. The IL28 polymorphism was not associated with 5 HCV RNA load in response to CQ. Preliminary evidence that CQ is possibly a safe treatment option for HCV nonresponders   ([@B114])
  N = 10\                                      Placebo 8 w                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  NCT02058173                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

R, randomized; DB, double-blind; OL, open label; PC, placebo-controlled; MC, multicenter; N, number of patients; d, day; w, week; m, month.

###### 

Published clinical trials based on autophagy modulation in cancer.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study Design/Registry Number                  Regimen                                                                                                                                                                                                                                                                                   Indication/Autophagy Biomarker                                                                                                                                                                                                                                                         Results                                                                                                                                                                                                                                                                                                                                                                                                                                        Reference
  --------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------
  Phase II, R, DB, PC\                          CQ: 500 mg/d\                                                                                                                                                                                                                                                                             Newly diagnosed breast cancer/not assessed                                                                                                                                                                                                                                             No significant difference in Ki67 index (a proliferation-associated nuclear antigen).                                                                                                                                                                                                                                                                                                                                                          ([@B7])
  N = 70\                                       Treatment: 14--29 d, 2--6 weeks before surgery                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  NCT02333890                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Phase I/II, OL\                               HCQ: 600 mg BID\                                                                                                                                                                                                                                                                          Clear-cell renal cell carcinoma (previously treated)/not assessed                                                                                                                                                                                                                      PR + SD: 67%; PR: 6%; PFS ≥ 6 m: 45%. The primary endpoint (\> 40% 6-month PFS rate) was met. HCQ is a tolerable inhibitor of autophagy.                                                                                                                                                                                                                                                                                                       ([@B51])
  N = 33\                                       Everolimus:10 mg/d                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT01510119                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Phase II, Simon's two-stage design; N = 21\   Pantoprazole: 240 mg/3w\                                                                                                                                                                                                                                                                  mCRPC/not assessed                                                                                                                                                                                                                                                                     PR = 31%; mOS = 15.7 m; median PFS = 5.3 m. Tolerable but clinical activity is insufficient.                                                                                                                                                                                                                                                                                                                                                   ([@B55])
  NCT01748500                                   Docetaxel: 75 mg/m^2^/3w                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Phase Ib/II, Single-arm, OL\                  HCQ: 200 mg BID/1--21\                                                                                                                                                                                                                                                                    mNSCLC/not assessed                                                                                                                                                                                                                                                                    ORR = 33% (44% in KRAS positive tumors); SD: 53%; PFS: 3.3 m (6.4 m in KRAS positive tumors). Addition of HCQ is safe and tolerable with a modest improvement in clinical responses.                                                                                                                                                                                                                                                           ([@B96])
  N = 40\                                       Day 1: Paclitaxel: 200 mg/m^2^\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  NCT01649947                                   Carboplatin: AUC = 6\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                Bevacizumab: 15 mg/kg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Phase I, OL\                                  HCQ: 200--600 mg BID\                                                                                                                                                                                                                                                                     Advanced solid tumors/pre-planned autophagy biomarkers are not assessed due to high attrition.                                                                                                                                                                                         SD: 15%; combination increases HCQ plasma levels.\                                                                                                                                                                                                                                                                                                                                                                                             ([@B102])
  N = 35\                                       MK-2206\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Combination therapy is tolerable but antitumor activity is minimal.                                                                                                                                                                                                                                                                                                                                                                            
  NCT01480154                                   135 0r 200 mg/w                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Phase 2, R, OL\                               HCQ: 600 mg BID\                                                                                                                                                                                                                                                                          Pancreatic cancer/not assessed                                                                                                                                                                                                                                                         HCQ: 12 m OS: non-HCQ: 41%; 49%, OS: 11.1 in HCQ; 12.1 in non-HCQ\                                                                                                                                                                                                                                                                                                                                                                             ([@B72])
  N = 112\                                      Gemcitabine hydrochloride +nab-paclitaxel (GA) with or without                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   PFS: 5.7 m HCQ; 6.4 m non-HCQ, ORR: 38.2% in HCQ; 21.1% in non-HCQ\                                                                                                                                                                                                                                                                                                                                                                            
  NCT01506973                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    HCQ did not improve the primary end point of OS but may play a role in the locally advanced setting, where tumor response may permit resection.                                                                                                                                                                                                                                                                                                

  Phase III, OL, R\                             CPI-613 + modified FOLFIRINOX (devimistat 500 mg*/*m^2^, oxaliplatin 65 mg*/*m^2^, irinotecan dose of 120 mg*/*m^2^; fluorouracil, 400 mg*/*m^2^ (bolus), then 2,400 mg*/*m^2^/2 w FOLFIRINOX (oxaliplatin, 85 mg*/*m^2^; irinotecan, 180 mg*/*m^2^; fluorouracil and leucovorin (same)   Metastatic adenocarcioma of pancreas/mitochondrial SOD2, PDK1-4, PDH, KGDH and CD79a and whole-exome sequencing                                                                                                                                                                        Objectives: evaluation of ORR and PFS; tumor response\                                                                                                                                                                                                                                                                                                                                                                                         ([@B115])
  N = 500\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Results are not yet available.                                                                                                                                                                                                                                                                                                                                                                                                                 
  NCT03504423\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  (AVENGER 500 trial)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Phase I, OL, cohort\                          HCQ: 100--200 mg BID\                                                                                                                                                                                                                                                                     Lymphangioleiomyomatosis/metabolomic profiling of polyamine metabolism 5′-methylthioadenosine and arginine                                                                                                                                                                             Upregulation of 5′-methylthioadenosine and arginine in the plasma of patients with LAM                                                                                                                                                                                                                                                                                                                                                         ([@B136])
  N = 14\                                       Sirolimus: 2 mg (trough levels between 5 and 15 ng/ml)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  NCT01687179                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Phase I, OL, cohort\                          HCQ: 100--200 mg BID\                                                                                                                                                                                                                                                                     Lymphangioleiomyomatosis/AXL receptor tyrosine kinase, brain-derived neurotrophic factor (BDNF), cathepsin D, epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2, insulin, receptor tyrosine protein kinase erbB3, and soluble superoxide dismutase 1   Only BDNF levels changed significantly. A consistent decrease of BDNF levels in comparison to baseline was observed which was not HCQ dosage-dependent.                                                                                                                                                                                                                                                                                        ([@B81])
  N = 14\                                       Sirolimus: 2 mg (trough levels between 5 and 15 ng/ml)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  24 w treatment + 24 w observation\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  NCT01687179                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  NR, OL\                                       None                                                                                                                                                                                                                                                                                      Endometriosis/LC3B-II                                                                                                                                                                                                                                                                  The expression of LC3B-II in ectopic endometrium group was significantly lower than that of its eutopic endometrium group. Down-regulated autophagy of ectopic endometrium in secretory phase may be related to the progression of EMs.                                                                                                                                                                                                        ([@B86])
  N = 30 (healthy)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  N = 43 (EM)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Phase I, OL\                                  CPI-613 (devimistat): 500 mg/m^2^/d\                                                                                                                                                                                                                                                      Metastatic pancreatic cancer/not assessed                                                                                                                                                                                                                                              MTD of CPI-613 = 500 mg/m^2^ per day.\                                                                                                                                                                                                                                                                                                                                                                                                         ([@B3])
  N = 20\                                       Modified FOLFIRINOX (oxaliplatin at 65 mg/m^2^, leucovorin at 400 mg/m^2^, irinotecan at 140 mg/m^2^, and fluorouracil 400 mg/m^2^ bolus followed by 2,400 mg/m^2^ over 46 h)                                                                                                                                                                                                                                                                                                                                                                                                    18 patients treated at MTD, ORR (CR + PR) = 61%. PFS = 9 m; mOS =19 m.\                                                                                                                                                                                                                                                                                                                                                                        
  NCT01835041                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Clinical activity requires Phase II validation.                                                                                                                                                                                                                                                                                                                                                                                                

  Phase III, R\                                 1\. TRIBE trial (discovery cohort)\                                                                                                                                                                                                                                                       mCRC/12 SNPs in eight autophagy-related genes were examined in this study (autophagy-related protein 13 \[ATG13\], ATG3, ATG5, ATG8, beclin 1, FIP200, ULK1 and UVRAG                                                                                                                  G allele of the FIP200 rs1129660 SNP showed a significantly lower rate of grades 2--3 hypertension compared with the A/A genotype.\                                                                                                                                                                                                                                                                                                            ([@B19])
  1. N = 219\                                   FOLFIRI (fluorouracil, leucovorin, and irinotecan) plus bevacizumab\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Polymorphisms in autophagy-related FIP200 gene may be predictive of hypertension.                                                                                                                                                                                                                                                                                                                                                              
  2. N = 234\                                   2. FIRE-3 trial (validation cohort)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  3. N = 204\                                   FOLFIRI plus bevacizumab\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  NCT00719797\                                  3. FIRE-3 trial (negative control) FOLFIRI plus cetuximab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  NCT00433927                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  OL, case report\                              188Re-liposome (0.42 ± 0.04 mCi/kg)                                                                                                                                                                                                                                                       Recurrent ovarian cancer/Cancer Antigen 125 (CA-125) as a marker of drug-resistance                                                                                                                                                                                                    188Re-liposome reduces CA-125 levels and improves survival.                                                                                                                                                                                                                                                                                                                                                                                    ([@B26])
  N = 2\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  NCT02271516                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Phase I, OL, cohort\                          HCQ: 100--200 mg BID\                                                                                                                                                                                                                                                                     Lymphangioleiomyo-matosis/not assessed                                                                                                                                                                                                                                                 Well tolerated; improvement in lung function at 24 weeks, with a decrease in lung function at the 48-week time point.                                                                                                                                                                                                                                                                                                                          ([@B33])
  N = 14; 24 w treatment + 24 w observation\    Sirolimus: 2 mg (trough levels between 5 and 15 ng/ml)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  NCT01687179                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Phase I/II, NR, OL\                           CQ: 250 mg/w and 500 mg/w × 4w                                                                                                                                                                                                                                                            Breast ductal carcinoma *in situ* (DCIS)/LC3B positive puncta                                                                                                                                                                                                                          Chloroquine reduces PCNA proliferation index in DCIS lesions and inhibits autophagic flux (LC3B positive puncta)                                                                                                                                                                                                                                                                                                                               ([@B38])
  N = 12\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  NCT01023477                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Phase I/II\                                   Ricolinostat: Phase I cohorts 1--6: 40, 80, 160, 240, and 360 mg on days 1--5 and 8--12 of each 21-day cycle. Bortezomib: 1.0 mg/m^2^/1.3 mg/m^2^. Dexamethasone                                                                                                                          Relapsed or refractory multiple myeloma/not assessed                                                                                                                                                                                                                                   Ricolinostat of 160 mg daily, the combination with bortezomib and dexamethasone is safe, well tolerated, and active.                                                                                                                                                                                                                                                                                                                           ([@B142])
  OL, R\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  N (ricolinostat) = 15\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  N (combined) = 57                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  OL, NR\                                       5-FU based treatment\                                                                                                                                                                                                                                                                     Gastric cancer/APE1 expression                                                                                                                                                                                                                                                         Expression of APE1 is associated with poor survival in gastric cancer patients. AT101, an APE1 inhibitor, may promote chemotherapeutic sensitivity.                                                                                                                                                                                                                                                                                            ([@B143])
  N = 65                                        (*In vitro* and *in vivo* clinical data with gossypol (AT-101) are linked to clinical data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Phase I, OL, NR\                              HCQ: 400 mg/day\                                                                                                                                                                                                                                                                          mCRC/CTSD and LC3-II in on study-biopsies                                                                                                                                                                                                                                              SD \> 16w: 26%; mPFS 2.8 m; mOS 6.7 m. Improved antitumor immunity (decreased exhausted and regulatory T cells and increased effector phenotype T cells) and reduced tumor autophagy                                                                                                                                                                                                                                                           ([@B111])
  N = 20\                                       Vorinostat: 600 mg/day                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  NCT01023737                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Phase Ib/OL, NR\                              Ricolinostat: 40--320 mg/d\                                                                                                                                                                                                                                                               Relapsed or refractory multiple myeloma/HDAC6                                                                                                                                                                                                                                          DLT: ricolinostat ricolinostat 160 mg BID. The pharmacokinetics of ricolinostat and lenalidomide were not affected by coadministration. ORR:55%                                                                                                                                                                                                                                                                                                ([@B150])
  N = 38\                                       Lenalidomide: 15--25 mg/d\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  NCT01583283                                   Dexamethasone: 40 mg/w                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Phase I, OL, NR\                              HCQ: 400 mg/d\                                                                                                                                                                                                                                                                            Stage IV refractory metastatic solid tumors/not assessed                                                                                                                                                                                                                               ORR=40%; SD:84%\                                                                                                                                                                                                                                                                                                                                                                                                                               ([@B27])
  N = 25                                        Sirolimus: 2 mg/d\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Tumor markers dropped \>50%. Progression from PD to PR:2; SD to PR:8\                                                                                                                                                                                                                                                                                                                                                                          
                                                Metronomic chemotherapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Autophagy is a promising target and warrants further Phase II studies                                                                                                                                                                                                                                                                                                                                                                          

  Phase II, OL, single arm\                     Sirolimus: 1 mg\                                                                                                                                                                                                                                                                          Sarcoma/uptake of \[^18^F\]-fluorodeoxyglucose positron emission tomography (FDG PET)                                                                                                                                                                                                  An inhibition of glycolysis within the tumors without tumor growth was noted.\                                                                                                                                                                                                                                                                                                                                                                 ([@B28])
  N = 10\                                       HCQ: 200 mg 2×1/d × 2 w                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          PR: 6/10; SD:3/10, PD:1/10.                                                                                                                                                                                                                                                                                                                                                                                                                    
  NCT01842594                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Phase II, OL\                                 12 cycles:HCQ: 600 mg BID+ FOLFOX (5-FU (400 mg/m^2^ bolus, then 2,400 mg/m^2^ over 46h) + leuco-vorin 200 mg/m^2^, oxaliplatin 85 mg/m^2^)/bevacizumab 5 mg/kg, all iv/2 w; after 12 cycles, no oxaliplatin.                                                                             Previously untreated mRCR/autophagy biomarkers in PBMC                                                                                                                                                                                                                                 Autophagy is inhibited in PBMCs.\                                                                                                                                                                                                                                                                                                                                                                                                              ([@B92])
  N = 19 (evaluable)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ORR: 52% (CR: 5%, PR: 47%)\                                                                                                                                                                                                                                                                                                                                                                                                                    
  NCT01206530                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    FOLFOX/bevacizumab + HCQ is an active regimen in mCRC.                                                                                                                                                                                                                                                                                                                                                                                         

  Phase I/II, OL, NR\                           HCQ: 1200 mg/d for 31 d\                                                                                                                                                                                                                                                                  Pancreatic adenocarcinoma/LC3-II in PBMC                                                                                                                                                                                                                                               No dose-limiting toxicities and no Grade 4/5 events related to treatment. 61% had a decrease in CA19-9. Patients with a \>51% increase of LC3-II in PBMC had improvement in PFS (15.03 *vs.* 6.9 months, p \< 0.05) and OS (34.8 *vs.* 10.8 m, p \< 0.05). Preoperative autophagy inhibition with HCQ plus gemcitabine is safe and well tolerated. Surrogate biomarker responses (CA 19-9) and surgical oncologic outcomes were encouraging.   ([@B23])
  N = 35\                                       Gemcitabine: 1,500 mg/m^2^ on days 3 and 17                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  NCT01128296                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Case series, OL, NR\                          CQ: 250 mg/d\                                                                                                                                                                                                                                                                             Recurrent glioblastoma                                                                                                                                                                                                                                                                 No CQ related toxicity. 2 PR, 1 SD, 1 PD. Encouraging responses were obtained.                                                                                                                                                                                                                                                                                                                                                                 ([@B21])
  N = 5                                         Reirradiation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Phase I, OL\                                  Pantoprazole: 80, 160, 240, and 360 mg *iv* prior to doxorubucin (60 mg/m2)                                                                                                                                                                                                               Solid tumors/not assessed                                                                                                                                                                                                                                                              Pantoprazole 240 mg with doxorubicin 60 mg/m^2^ every 3 weeks: toxicity was predictable and manageable.                                                                                                                                                                                                                                                                                                                                        ([@B24])
  N = 24                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Phase I, OL, cohort\                          HCQ: 400--800 mg/d (d2--d21)\                                                                                                                                                                                                                                                             Advanced solid tumors/AV, lysosomal protease CTSD, CDKN1A                                                                                                                                                                                                                              HCQ and VOR stimulate the expression of CTSD and CDKN1A and the accumulation of autophagic vacuoles in PBMC. HCQ addition had no significant impact on the pharmaco-kinetic profile of VOR. 46% had PR or SD for ≥2 cycles. Based on the safety and preliminary efficacy of this combination, additional clinical studies are currently being planned                                                                                          ([@B94])
  N = 24\                                       Vorinostat: 400 mg/d (d1--21)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  NCT01023737                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Phase Ib/II, OL\                              HCQ: 1200 mg/d\                                                                                                                                                                                                                                                                           Advanced solid tumors and melanoma/AV accumulation in PBMC.                                                                                                                                                                                                                            Significant AV accumulation with TEM + HCQ compared with baseline only with 1200 mg cohort. SD = 74%; further studies are warranted. TEM and HCQ: safe and tolerable, modulate autophagy in patients, and have significant antitumor activity.                                                                                                                                                                                                 ([@B119])
  N = 27                                        Temsirolimus: 25 mg/w                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Phase Ib/II, OL\                              HCQ:1200 mg/d\                                                                                                                                                                                                                                                                            Advanced solid tumors and melanoma/autophagic vacuoles peripheral blood mononuclear cells                                                                                                                                                                                              PR = 14%; SD: 27% in 22 evaluable patients with advanced melanoma. Prolonged stable disease and responses suggest antitumor activity in melanoma patients.                                                                                                                                                                                                                                                                                     ([@B120])
  N = 40                                        Temozolomide: 150 mg/m^2^ daily for 7/14 d                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Phase I/II\                                   HCQ: 200--800 mg/d\                                                                                                                                                                                                                                                                       Newly diagnosed gliablastoma multiforme/AV and LC3-II                                                                                                                                                                                                                                  MTD of HCQ: 600 mg/d. 800 mg/d: Grades 3--4 neutropenia and thrombocytopenia; OS 12 m = 70%; OS 18 m = 36%; OS 24 m = 25%. HCQ-induced dose dependent increases in AV and LC3-II in PBMC. Autophagy was not consistently achieved. No significant improvement in overall survival.                                                                                                                                                             ([@B126])
  OL\                                           Temozolomide: initially before RT-75 mg/m(2); maintenance-150 mg/m(2)/d; 5 d/m for 6 m.\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  N (Phase I) = 16\                             RT: 60 Gy in 30 fractions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  N (Phase II) = 76\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  NCT00486603                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Phase Ib/II, OL\                              HCQ: 1,200 mg/d\                                                                                                                                                                                                                                                                          Relapsed/refractory myeloma/AV accumulation and LC3-II in PBMC                                                                                                                                                                                                                         Therapy-induced AV accumulation in bone marrow plasma cells. PR = 14%, MR = 14%, SD = 45%; further studies are warranted.                                                                                                                                                                                                                                                                                                                      ([@B141])
  N = 25                                        Bortezomib: 1.3 mg/m^2^                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Phase II\                                     HCQ: 800 and 1,200 mg/d\                                                                                                                                                                                                                                                                  Metastatic pancreatic adenocarcinoma (previously treated)/LC3-II in lymphocytes                                                                                                                                                                                                        Analysis of LC3-II showed inconsistent autophagy inhibition. SD: 10%; PFS: 46.5 d; OS: 69 d. Negligible therapeutic efficacy.                                                                                                                                                                                                                                                                                                                  ([@B147])
  OL\                                           Previously treated with other regimens                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  N = 20\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  NCT01273805                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Phase II\                                     CQ: 150 mg/d × 4 w\                                                                                                                                                                                                                                                                       Brain metastases from solid tumors/not assessed                                                                                                                                                                                                                                        ORR = CLQ-54%; PL-55%.\                                                                                                                                                                                                                                                                                                                                                                                                                        ([@B125])
  R, PC, DB\                                    WBI (30 Gy in 10 fractions/d over 2 weeks)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       PFS = CLQ-84%; PL-55%\                                                                                                                                                                                                                                                                                                                                                                                                                         
  N = 73\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        CLQ + WBI improved the control of brain metastasis with no increase in toxicity. CLQ did not improve the RR or OS.                                                                                                                                                                                                                                                                                                                             
  NCT01894633                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Pilot, single cohort\                         CQ: 250 mg/day × 5 w; started 1 w before WBRT                                                                                                                                                                                                                                             Newly diagnosed brain metastases from solid tumors                                                                                                                                                                                                                                     CR = 2; PR = 12; SD = 1\                                                                                                                                                                                                                                                                                                                                                                                                                       ([@B34])
  N = 20                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         No treatment-related grade ≥ 3 toxicities or treatment interruption due to toxicity. Median/mean OS = 5.7 and 8.9 m                                                                                                                                                                                                                                                                                                                            

  Phase Ib/II, OL\                              2-deoxyglucose (2-DG)\                                                                                                                                                                                                                                                                    mCRPC/p62 as marker of 2-DG resistance                                                                                                                                                                                                                                                 P62 decreased in 83% and fluorodeoxyglucose uptake decreased in 63% of patients. 2-DG alone or in combination can be used to target tumor metabolism.                                                                                                                                                                                                                                                                                          ([@B131])
  N = 12                                        45 mg/kg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Phase II, OL\                                 Sorafenib: 400 mg × 2/d                                                                                                                                                                                                                                                                   Relapsed or refractory lymphoma/\                                                                                                                                                                                                                                                      ORR: 13%; OS: 16 m. LC3-II levels at baseline were signiﬁcantly higher in responsive patients than in nonresponsive patients. PBLs: responsive patients: reduction in LC3-II levels; nonresponsive patients: no change.                                                                                                                                                                                                                        ([@B50])
  N = 30                                                                                                                                                                                                                                                                                                                                  LC3‐II in PBLs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Phase I, OL, R\                               HCQ: 400--1000 mg/d (escalated)\                                                                                                                                                                                                                                                          Advanced NSCLC/not assessed                                                                                                                                                                                                                                                            HCQ with or without erlotinib was safe and well-tolerated. The recommended phase 2 dose: HCQ 1000mg + erlotinib 150mg.                                                                                                                                                                                                                                                                                                                         ([@B48])
  N(HCQ) = 27\                                  Erlotinib: 150 mg/d                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  N(HCQ + Erlotinib) = 19\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  NCT01026844                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Phase II, R, DB, PC\                          CQ: 150 mg/d\                                                                                                                                                                                                                                                                             Glioblastoma multiforme                                                                                                                                                                                                                                                                OS = 24m for CQ; 11m for PL\                                                                                                                                                                                                                                                                                                                                                                                                                   ([@B130])
  N = 30\                                       Conventional chemotherapy + radiotherapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Small sample size suggests larger, more definitive studies.                                                                                                                                                                                                                                                                                                                                                                                    
  NCT00224978                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

R, randomized; DB, double-blind; OL, open label; PC, placebo-controlled; MC, multicenter; N, number of patients; d, day; w, week; m, month; RT, Radiotherapy; PL, placebo; HCQ, hydroxychloroquine; CQ, chloroquine; OS, overall survival; ORR, objective response rate; CR, complete response; PR, partial response; MR, minor response; SD, stable disease; PFS, progression-free survival.

mCRPC, metastatic castration-resistant prostate cancer; mNSCLC, metastatic nonsmall cell lung cancer; mCRC, metastatic colorectal cancer; PBMC, peripheral blood mononuclear cells; AV, autophagic vacuole; UVRAG, UV radiation resistance-associated gene protein; FIP200, focal adhesion kinase family interacting protein of 200 kDa; ULK1, unc-51-like kinase 1; CDKN1A, cyclin-dependent kinase inhibitor 1A.

###### 

Registered clinical trials based on autophagy modulation in various diseases.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  NCT number    Study Design                                                 Title                                                                                                                                                                                 Regimen                                                                                                         Study Start/Study End                  Result
  ------------- ------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------- -------------------------------------- -----------------------------------------------------------------------------------------------------------------------
  NCT04160455   Observational model: cohort                                  Study of autophagy and the effects of GALIG gene products in HIV-1 infected patients who are under antiretroviral therapy since primary-infection, chronic phase, or never treated.   HIV-1 infected patients under antiretroviral therapy since primary-infection, chronic phase, or never treated   November 7, 2019/November 7, 2029      Recruiting

  NCT04138134   Observational model: cohort                                  Autophagy and venous endothelial function                                                                                                                                             Spermidine                                                                                                      December 1, 2019/June 1, 2020          Not yet recruiting

  NCT03979651   NR, OL                                                       MEK and autophagy inhibition in metastatic/locally advanced, unresectable neuroblastoma RAS (NRAS) melanoma                                                                           Trametinib plus HCQ                                                                                             September 30, 2019/March 31, 2022      Ongoing

  NCT00786682   Phase II, NR, OL                                             Docetaxel and hydroxychloroquine in treating patients with metastatic prostate cancer                                                                                                 Docetaxel and HCQ                                                                                               December 2008--October 2012            The study was stopped due to lack of improved efficacy compared to historical controls.

  NCT00765765   Phase I/II, NR, OL                                           Ixabepilone and hydroxychloro-quine in treating patients with metastatic breast cancer                                                                                                Ixabepilone and HCQ                                                                                             February 2009--December 2012           The study was closed early due to slow accrual

  NCT00969306   Phase I, NR, OL                                              Chloroquine as an antiautophagy drug in stage IV small cell lung cancer (SCLC) patients                                                                                               Chloroquine                                                                                                     September 2013--June 2016              Terminated but no results posted

  NCT03037437   Phase II, NR, OL                                             Sorafenib induced autophagy using hydroxychloroquine in hepatocellular cancer                                                                                                         Sorafenib + HCQ                                                                                                 February 16, 2017--December 2020       Ongoing

  NCT01480154   Phase I, NR, OL                                              Akt inhibitor MK2206 and hydroxychloroquine in treating patients with advanced solid tumors, melanoma, prostate or kidney cancer                                                      MK2206 + HCQ                                                                                                    November 23, 2011--December 2019       ([@B102])

  NCT01510119   Phase I/II, NR, OL                                           Autophagy inhibition to augment mTOR Inhibition: A Phase I/II Trial of RAD001 and hydroxychloroquine in patients with previously treated renal cell carcinoma                         RAD001 (everolimus) + HCQ                                                                                       September 2011--January 2017           ([@B51])

  NCT01023737   Phase I, NR, OL                                              Hydroxychloroquine + Vorinostat in advanced solid tumors                                                                                                                              HCQ + Vorinostat                                                                                                November 2009--September 2020          ([@B111])

  NCT03598595   Phase I/II, NR, OL                                           Gemcitabine, docetaxel, and hydroxychloroquine in treating participants with recurrent or refractory osteosarcoma                                                                     Gemcitabine, Docetaxel, and HCQ                                                                                 January 28, 2019--March 2, 2020        Ongoing

  NCT02631252   Phase I, NR, OL                                              Phase I Study of mitoxantrone and etoposide combined with hydroxychloroquine, for relapsed acute myelogenous leukemia                                                                 Mitoxantrone and Etoposide and HCQ                                                                              August 18, 2016--October 2, 2017       Terminated due to inability to accrue.

  NCT03774472   Phase I, NR, OL                                              Hydroxychloroquine, palbociclib, and letrozole before surgery in treating participants with estrogen receptor positive, HER2 negative breast cancer                                   HCQ, Palbociclib, and Letrozole                                                                                 August 20, 2018--December 31, 2020     Ongoing

  NCT02339168   Phase I, NR, OL                                              Enzalutamide and metformin-hydrochloride in treating patients with hormone-resistant prostate cancer                                                                                  Enzalutamide and Metformin-Hydrochloride                                                                        June 2016--July 2020                   Ongoing

  NCT01594242   Phase I, NR, OL                                              Autophagy induction after bortezomib for myeloma                                                                                                                                      Bortezomib                                                                                                      July 10, 2012--March 2, 2015           Completed but no results are available

  NCT03700424   Phase II, R, quadruple-blind                                 Inflammation reduction by Trehalose administration (in acute coronary syndrome)                                                                                                       Trehalose vs normal saline infusion weekly (15 g/week) for a period of 12 weeks                                 July 7, 2019--June 2020                Ongoing

  NCT01266057   Phase I, NR, OL                                              Sirolimus or vorinostat and hydroxychloroquine in advanced cancer                                                                                                                     Sirolimus or Vorinostat\                                                                                        April 28, 2011--February 2021          Ongoing
                                                                                                                                                                                                                                                                   and HCQ                                                                                                                                                

  NCT02378532   Phase I, NR, OL                                              The addition of chloroquine to chemoradiation for glioblastoma                                                                                                                        Chloroquine + temozolomide + chemoradiation                                                                     August 2016--June 2019                 Ongoing (still recruiting)

  NCT01006369   Phase II, NR, OL                                             Hydroxychloroquine, capecitabine, oxaliplatin, and bevacizumab in treating patients with metastatic colorectal cancer                                                                 HCQ, Capecitabine, Oxaliplatin, and Bevacizumab                                                                 May 2009--April 27, 2016               Completed but results are not yet available

  NCT03309007   Phase III, R, quadruple-blind                                A double-blind, placebo-controlled trial of anti-aging, pro-autophagy effects of metformin in adults with prediabetes                                                                 Metformin Placebo                                                                                               September 1, 2017--July 31, 2021       Active, not recruiting

  NCT02042989   Phase I, NR, OL                                              MLN9708 and Vorinostat in patients with advanced p53 mutant malignancies                                                                                                              MLN9708 and Vorinostat                                                                                          June 27, 2014--June 2022               Active, not recruiting

  NCT00728845   Phase I/II, NR, OL                                           Hydroxychloroquine, carboplatin, paclitaxel, and bevacizumab in recurrent advanced nonsmall cell lung cancer                                                                          HCQ, Carboplatin, Paclitaxel, and Bevacizumab                                                                   June 16, 2008--December 21, 2010       Terminated due to slow accrual

  NCT03754179   Phase I/II, R, OL                                            Dabrafenib/trametinib/hydroxychloroquine for advanced pretreated BRAF V600 mutant melanoma                                                                                            Dabrafenib/Trametinib/HCQ                                                                                       January 23, 2018--December 2020        Recruiting

  NCT02316340   Phase II, R, OL                                              Vorinostat Plus hydroxychloroquine *vs* regorafenib in colorectal cancer                                                                                                              Vorinostat + HCQ *vs* Regorafenib                                                                               February 2015--September 2020          Active, not recruiting

  NCT02432417   Phase II, R, OL                                              The addition of chloroquine to chemoradiation for glioblastoma,                                                                                                                       Chloroquine + Chemoradiation                                                                                    January 2020--January 2024             Not yet recruiting

  NCT02257424   Phase I/II, NR, OL                                           Dabrafenib, trametinib, and hydroxychloroquine in patients with advanced BRAF mutant melanoma                                                                                         Dabrafenib, Trametinib and HCQ                                                                                  October 2014--October 2026             Active, recruiting

  NCT02421575   Phase I, NR, OL                                              Hydroxychloroquine in blocking autophagy in patients with prostate cancer undergoing surgery or active surveillance                                                                   HCQ                                                                                                             July 2012--February 26, 2016           Terminated due to slow accrual

  NCT01206530   Phase I/II                                                   FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer                                                                                                                      HCQ, Oxaliplatin, Leuco-vorin, 5-fluorouracil, Bevacizumab                                                      September 2010 --September 2017        ([@B92])

  NCT00962845   Phase I, NR, OL                                              Hydroxychloroquine in patients with stage III or stage IV melanoma that can be removed by surgery                                                                                     HCQ                                                                                                             September 2010--May 2013               Early Phase I is completed. Last update September, 2018. <https://ichgcp.net/es/clinical-trials-registry/NCT00962845>

  NCT01144169   Phase I, NR, O                                               Study of hydroxychloroquine before surgery in patients with primary renal Cell carcinoma                                                                                              HCQ                                                                                                             October 2010--September 2016           Terminated due to barriers to accrual such as delay until surgery and additional preoperative visits

  NCT03094546   Phase III, R, triple-blind                                   Polyamine-enriched diet in elderly individuals with subjective cognitive decline                                                                                                      Polyamine-rich diet                                                                                             June 2019 -- June 2020                 ([@B146])

  NCT01583283   A Phase I/II, Open Label, Multi-center Study                 Study of ACY-1215 in combination with lenalidomide, and dexamethasone in multiple myeloma                                                                                             Ricolinostat (*ACY*-*1215*) Lenalidomide Dexamethasone                                                          July 12, 2012--December 31, 2019       ([@B150])

  NCT01997840   Phase 1B/2 Multi-Center, Open Label, Dose-escalation Study   ACY-1215 (ricolinostat) in combination with pomalidomide and low-dose dex in relapsed-and-refractory multiple myeloma                                                                 ACY-1215 (ricolinostat) in combination with pomalidomide and dexamethasone                                      March 1, 2014--January 27, 2021        Active, not recruiting

  NCT02189343   Phase 1b Multi-Center, Open Label, Dose-Escalation Study     Phase 1b Study evaluating ACY-1215 (ricolinostat) in combination with pomalidomide and dexamethasone in relapsed or relapsed-and-refractory multiple myeloma                          ACY-1215 (Ricolinostat) Pomalidomide Dexamethasone                                                              September 15, 2014--January 30, 2019   Active, not recruiting
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

R, randomized; DB, double-blind; OL, open label; PC, placebo-controlled; MC, multicenter; N, number of patients; d, day; w, week, m, month; RT, Radiotherapy; PL, placebo; HCQ, hydroxychloroquine; CQ, chloroquine; OS, overall survival; ORR, objective response rate; CR, complete response; PR, partial response; MR, minor response; SD, stable disease; PFS, progression-free survival.

As seen in [**Tables 3**](#T3){ref-type="table"} and [**4**](#T4){ref-type="table"}, the role of autophagy in the prognosis of various diseases received increasing interest, especially in the last decade. Various biomarkers were utilized in these clinical trials to measure autophagy response. In the early studies, autophagic vacuoles were evaluated by transmission electron microscopy, but this method was unreliable ([@B85]). Selected biomarkers of autophagy include microtubule associated protein light chain 3 (LC3), p62, ATGs in peripheral blood mononuclear cells (PBMCs), lymphoblasts, and fibroblasts of patients. Proteomics, metabolomics, lysosomal protease cathepsin D (CTSD), cyclin-dependent kinase inhibitor 1 (CDKN1A, p21/cip1/waf1), and S6RP phosphorylation are among the potential biomarkers considered.

Cancer {#s4_2}
------

Cancer is the extensively studied field in autophagy ([**Table 4**](#T4){ref-type="table"}). CQ and HCQ are mostly included in treatment regimens to increase the sensitivity of chemotherapeutics. CQ treatment at a relatively high daily dose of 500 mg resulted in no significant difference in the classic cellular proliferation marker, Ki67 index, in newly diagnosed breast cancer patients in a Phase II, double-blind, randomized trial ([@B7]). CQ at a daily dose of 150 mg was able to reduce the proliferating cell nuclear antigen (PCNA) index in breast ductal carcinoma ([@B38]). CQ at 150 mg/day together with conventional chemotherapy plus radiotherapy improved overall survival when compared to placebo in glioblastoma multiforme (GBM), but the small sample size of 30 patients was not sufficient for reaching a conclusion ([@B130]). A higher dose of CQ (250 mg/day) added to radiotherapy gave encouraging results in a pilot study of five patients with GBM ([@B21]). A small size study, which enrolled newly diagnosed brain metastasis patients, showed that CQ at 250 mg/day, starting 1 week before radiotherapy and continuing for 5 weeks, was well tolerated with a PR rate of 60% ([@B34]). In comparison, CQ at a daily dose of 150 mg for four weeks plus radiotherapy, when compared to placebo, also improved brain metastasis control and prolonged progression free survival (PFS),but achieved no benefit in terms of response rate or overall survival ([@B125]).

Combination of HCQ with mTOR inhibitors, which enhance cytoprotective autophagy, was tested in Phase I/IIa trials. HCQ in combination with everolimus was tolerable and the primary endpoint of a 6-month progression free survival (PFS) rate over 40% was met in clear cell renal carcinoma ([@B51]). HCQ in combination with sirolimus significantly increased the "forced expiratory volume" but not the "forced vital capacity" in lymphangioleiomyomatosis ([@B33]). Metabolomic profiling of polyamine metabolism (upregulation of 5′-methylthioadenosine) and brain derived neurotrophic factor were suggested as candidate markers associated with autophagy in lymphangioleiomyomatosis ([@B81]; [@B136]). HCQ combined with temsirolimus showed significant antitumor activity in advanced solid tumors and melanoma ([@B119]). HCQ and sirolimus decreased glycolysis mainly in cancer associated fibroblasts, hence attenuated their metabolic-parasite relationship with sarcoma cells; this double autophagy modulation resulted in an overall response rate (ORR) of 90% ([@B28]). Addition of sirolimus and HCQ to the ongoing metronomic chemotherapy, to which patients were previously unresponsive, resulted in high salvage rates in stage IV refractory metastatic tumors ([@B27]).

HCQ alone or in combination provided minimal to modest benefit with the EGFR inhibitor erlotinib in metastatic nonsmall cell lung cancer ([@B48]; [@B96]); with FOLFOX/bevacizumab in metastatic colorectal cancer ([@B92]); with temozolomide in advanced solid tumors and melanoma ([@B120]); with vorinostat ([@B94]; [@B111]) and MK-2206 ([@B102]) in advanced solid tumors; as a single agent ([@B147]), with gemcitabine ([@B23]) and with gemcitabine plus nab-paclitaxel ([@B72]) in advanced pancreatic cancer; with temozolomide plus radiotherapy in newly diagnosed glioblastoma multiforme ([@B126]) and with bortezomib in refractory myeloma ([@B141]).

Ricolinostat, a selective HDAC6 inhibitor, was well tolerated and moderately effective in combination with bortezomib ([@B142]) and the immunomodulator lenalidomide plus dexamethasone ([@B150]) in refractory multiple myeloma.

The proton pump inhibitor, pantoprazole, was tolerable when combined with doxorubicin in solid tumors ([@B24]) but showed insufficient clinical activity when combined with docetaxel in metastatic castration resistant prostate cancer (mCRPC) ([@B55]).

Two novel drugs seem to be promising as autophagy inhibitors. Devimistat (CPI-613) inhibits two key enzymes of the tricarboxcylic acid cycle, *i.e.* pyruvate dehydrogenase and ketoglutarate dehydrogenase, and thus impairs pancreatic cell mitochondrial metabolism. Devimistat, in combination with the FOLFIRINOX regimen, exhibited an ORR of 61% ([@B3]) in a Phase I trial and is also under evaluation in a large scale Phase III trial (AVENGAR 500) in metastatic pancreas adenocacinoma ([@B115]). ^188^Re-liposome treatment was successful in inducing mitochondrial autophagy and improved survival in two cases with recurrent ovarian cancer ([@B26]).

Natural products were also investigated as autophagy modulators. Spermidine, a natural polyamine, triggers autophagy by inducing the acetylation or deacetylation of autophagy-related genes ([@B149]). Spermidine-based nutritional supplementation, leading to the acetylation or deacetylation of autophagy related genes, is considered as an autophagy-based strategy against memory under-performance, mnemonic discrimination ability and cognitive decline in the elderly ([@B145]; [@B146]). Gossypol (AT-101) is a polyphenolic compound extracted from cotton. In addition to its contraceptive and anti-infective effects, its roles as an anticancer agent by targeting apoptotic and autophagic pathways have also been studied in the last decade. It is a pan-Bcl-2 inhibitor and induces autophagy by liberating Beclin-1 from Bcl2 ([@B112]). Most of the clinical studies in PubMed focused on its apoptotic effect; only Wei et al. reported that the expression of apurinic/apyrimidinic endonuclease (APE1), which regulates the DNA base excision repair process, reduces survival in gastric cancer patients and the APE1 inhibitor AT-101 may be a potential sensitizer for 5-fluorouracil ([@B143]). Curcumin, the major constituent of Curcuma longa (turmeric), and quercetin, a plant flavonol, are two other autophagy inducers, which inhibit the Akt/mTOR pathway. No phase trial on autophagy is yet registered with the above-mentioned natural compounds in the NCT database, except for spermidine ([@B77]; [@B112]).

Autophagy related polymorphisms might be predictive of anticancer treatment associated adverse effects. Berger et al. reported that FIP200 gene polymorphisms might predict bevacizumab-induced hypertension ([@B19]).

In summary, the application of autophagy inducers/inhibitors in cancer treatment is a quickly growing area of research, which has the aim of balancing the potentially good and bad effects. The success in keeping this balance will determine the future development and use of such compounds.

Neurodegenerative Disorders {#s4_3}
---------------------------

In amyotrophic lateral sclerosis (ALS), degradation of mutant protein aggregates and damaged organelles is disrupted. Two autophagy modulators, colchicine, which upregulates autophagy-related proteins in motor neurons in combination with riluzole ([@B98]), and the mTOR inhibitor rapamycin (sirolimus) ([@B97]) are being evaluated for their therapeutic efficacy against ALS in two separate double-blind, randomized, placebo-controlled phase-II trials.

Infectious Diseases {#s4_4}
-------------------

The mycobacterium tuberculosis virulence is associated with perturbations in the autophagy process and AMPK signaling. Novita et al. showed that metformin enhances the bactericidal effect of anti-tuberculosis treatment *via* autophagy in patients with tuberculosis and diabetes ([@B109]). Another study was designed to assess the effect of metformin by means of a detailed autophagy biomarker panel in tuberculosis ([@B110]). Chloroquine significantly decreased HCV-RNA in Hepatitis C in a quadruple-blind, randomized Phase IV study ([@B114]).

Alkylphosphocholines {#s5}
====================

Synthetic APCs include miltefosine, perifosine, and erufosine, which correspond to the first, second, and third generations of APCs (see [**Figure 3**](#f3){ref-type="fig"}). They are derived from alkylphospholipids (ALPs) or 'synthetic antitumor lipids', which include edelfosine and ilmofosine. The two related groups of antitumor agents target cell membranes rather than DNA ([@B140]). ALPs are metabolically stable, nonmutagenic and versatile drugs derived from lysophosphatidylcholine ([@B68]; [@B156]). All agents possess long hydrocarbon chains that slow their catabolism ([@B139]).

![Structures and names of alkylphosphocholines.](fphar-11-00547-g003){#f3}

Cancer researchers became interested in APCs during the 80s of the last century for their selective and high anticancer efficacy in autochthonous, methylnitrosourea-induced rat mammary carcinoma ([@B15]; [@B106]), which was later confirmed in 7,12-dimethylbenzanthracene-induced rat mammary carcinoma ([@B57]). This unusual spectrum of activity pointed to an influence of APCs on the ras signaling chain, as both chemically induced models exhibit point mutations in the ras gene as driving force for tumor development. In subsequent years, this assumption was confirmed ([@B16]; [@B18]; [@B32]). Apart from breast cancer models, tumor cell lines from other cancer types were sensitive to ALPs, as well ([@B35]; [@B63]; [@B79]; [@B47]).

The first generation of APCs, the prototype of which is miltefosine, possesses a typical phosphocholine polar moiety and a saturated alkyl chain of varying length ([@B15]; [@B17]). The second generation includes perifosine, which has a cyclic polar head and saturated alkyl chain ([@B58]). Finally, the third generation possesses a classic or modified phosphocholine polar moiety and an unsaturated alkyl chain. The best-known representative of this group is erufosine ([@B68]).

An ether linkage to its glycerol backbone characterizes the prototype of ALPs, edelfosine ([@B68]; [@B156]). The first APC generation is represented by miltefosine (hexadecylphosphocholine, HPC), which lacks the glycerol backbone and thus shows a less complex metabolism ([@B68]; [@B156]). In order to reduce the acetylcholine-like side effects observed for derivatives with a phosphocholine headgroup, as miltefosine, perifosine contained a piperidine moiety instead of phosphocholine and thus showed less side effects in clinical applications. Erufosine represents the most novel generation of APCs, which are characterized by a chain length of 22 carbons and the presence of a single double bond ([@B41]; [@B78]; [@B67]; [@B68]; [@B156]). At clinical concentrations, APCs disturb cell membranes and hamper their phospholipid turnover as well as lipid-based signal and transduction pathways. They may interfere with signaling by hindering the contact of proteins with other cell membrane proteins, or with distinct membrane lipids or lipid microdomains. At high concentrations, they may cause cell lysis owing to their detergent properties ([@B140]). APCs hinder the normal lipid metabolism and lipid dependent signal transduction by their accumulation in cell membranes. Therefore, they can induce apoptosis in rapidly growing cells, such as tumor cells. They can lead to selective reduction of tumor metastases, impairment of angiogenesis, differentiation of tumor cells, impediment of cytokinesis, cell cycle halt, immune stimulation and intensification of immune reactions against tumors ([@B139]; [@B80]; [@B68]; [@B156]). Among their mechanism of actions are interference with phospholipid metabolism, the inhibition of survival pathways and alteration of signal transduction (*e.g.* SAPK/JNK AKT-mTOR Ras/Raf, PKC), activation of pro-apoptotic signaling through ALP-triggered stress, and ALP-stimulated Fas/CD95 assembly in lipid rafts ([@B140]; [@B80]). This group of drugs interferes with cell division without inhibiting nuclear division, causing increased percentages of cells in the G2/M phase of the cell cycle, with multinucleate cell formation, and ensuing apoptotic cell death ([@B80]).

Modulation of Phosphatidylinositol 3-Kinase/Akt/mTOR Signaling by APCs {#s5_1}
----------------------------------------------------------------------

The PI3K/Akt/mTOR pathway is an important regulator of cell survival, which is activated by receptor tyrosine kinases (RTKs). Following stimulation by growth factors, dimerization of the RTKs triggers an autophosphorylation process and activates PI3K. PIP2 (phosphatidylinositol-3,4-bisphosphate) is then converted to PIP3 (phosphatidylinositol-3,4,5-triphosphate) by PI3K ([@B157]). PI3K signaling is inhibited through the de-phosphorylation of PIP3 by PTEN (tumor suppressor phosphatase and Tensin homolog deleted on chromosome 10) ([@B91]). PIP3 binds to the pleckstrin homology (PH) domain of the serine/threonine kinase Akt, leading to its allosterical activation. At the next step, phosphorylated Akt (p-Akt) activates mTOR, the key inhibitor of autophagy. Therefore, APCs, by inhibiting Akt, induce autophagy *via* Akt/mTOR signaling pathway ([**Figure 2**](#f2){ref-type="fig"}) ([@B68]). Additionally, perifosine inhibits mTOR signaling by promoting degradation of mTOR, raptor, and rictor (Sun, 2010).

Miltefosine inhibits phosphorylation of Akt at its Ser^473^ residue in A431 epidermoid carcinoma cells, which were stimulated by insulin ([@B128]). The related PI3K/Akt signaling has also been implicated in various viral infections. Miltefosine inhibits Chikungunya virus replication by inhibiting Akt phosphorylation in human primary dermal fibroblasts (Sharma et al., 2018). Primary effusion lymphoma (PEL) displays activated PI3K/Akt/mTOR signaling. Both perifosine and miltefosine inhibit proliferation of PEL cell lines and retarded PEL tumor progression *in vivo* ([@B20]).

Perifosine prevents membrane recruitment of Akt and displaces PIP2 and PIP3 from this enzyme. As a result, Akt can no longer proceed through the required conformational change, for its dual phosphorylation, hence activation ([@B140]). Perifosine blocks phosphorylation of constitutively active Akt within 3 h and also S6 kinase within 6 h in PTEN-mutant human glioma cell lines T98G and U373MG ([@B104]). Perifosine decreases phosphorylated Akt levels in a dose- and time-dependent manner in the aggressive thyroid cancer cell line FTC133 that has genetic alterations in the PI3K/Akt pathway ([@B91]). Inhibition of aberrant PI3K/Akt signaling by perifosine in various cancer types including thyroid cancer ([@B91]), renal cell carcinoma (Porta and Figlin, 2009), neuroblastoma (Sun and Modak, 2012), neuroendocrine tumors (Zitzmann et al., 2012), mantle cell lymphoma (Reis-Sobreiro et al., 2013), and multiple myeloma ([@B29]) seems to be a promising therapeutic strategy. Perifosine also plays a protective role against kainic acid-induced epileptogenesis, which involves abnormal activity of the mTOR pathway. Perifosine pretreatment significantly decreases p-Akt/Akt and p-S6/S6 ratios which results in marked decrease of spontaneous seizure frequency and neuronal death (Zhu et al., 2018)

Erufosine can be infused systemically and shows penetration through the blood brain barrier ([@B36]; [@B99]). Erufosine inhibits the aberrant PI3K/Akt/mTOR signaling pathway in various cancer types including leukemia, oral squamous cell carcinoma, glioma and prostate cancer ([@B35]; [@B127]; [@B70]; [@B9]; [@B71]; [@B4]; [@B8]). Remarkably, erufosine was less toxic to normal bone marrow than to cancer cells ([@B10]; [@B152]). Phosphorylation of PKB/Akt is linked to several proliferation pathways, which are inhibited, correspondingly \[for overview see ([@B68])\]. Erufosine prevents the Akt--mTOR pathway reactivation and development of drug resistance because it targets this pathway at multiple levels. Firstly, it induces dephosphorylation of PKB/Akt at Ser^473^, thus inhibiting the mTORC2 complex. Furthermore, it reduces the phosphorylation of PKB/Akt at its Thr^308^ residue, the upstream kinase activator of the mTORC1 complex. In addition, erufosine causes a dose-dependent decrease in p-PTEN levels, with total PTEN levels remaining unaffected, dephosphorylation of p-mTOR at Ser^2448^, with total mTOR expression levels remaining unaffected. Erufosine also dephosphorylates other constituents of the mTORC1 complex, such as p-PRAS40 and p-Raptor in a concentration-dependent manner, as well as the downstream substrates of mTORC1, *i.e.* p70S6K and p-4EBP1. Knockdown of mTOR by siRNA enhances the cytotoxic potential of erufosine ([@B71]). The effects of erufosine on mTOR explain the dose-dependent induction of autophagy observed with this drug. In addition to these effects, erufosine induces cell cycle arrest in combination with its activity on the Rb gene ([@B155]; [@B6]).

Autophagy and Alkylphosphocholines {#s5_2}
----------------------------------

### Miltefosine {#s5_2_1}

Miltefosine, the first generation APC, is the only oral drug used for the treatment of leishmaniasis. In trypanosomatids, the shift in balance between posttranslational modifications, polyglutamylation, and deglutamylation may determine cell death and autophagic survival, respectively. Overexpression of polyglutamylases increases miltefosine-induced cell-death, whereas overexpression of deglutamylases, CCP5A and CCP5B, increases miltefosine-induced cell survival process of autophagy ([@B12]).

Atherosclerosis is driven by deposition of LDL in the arterial intima, which triggers endothelial cell activation and inflammation followed by the activation of toll-like receptor (TLR) pathways and the assembly of the NLRP3 inflammasome. Autophagy and cholesterol efflux, which deteriorate with age, are important protective mechanisms against atherosclerosis. Miltefosine activates AMPK and ULK1, inhibits TLR signaling pathway, and reduces NLRP3 inflammasome assembly. In this regard, autophagy enhancement by APCs may have a therapeutic potential in atherosclerosis ([@B60]).

Miltefosine enhances autophagy in cutaneous T-cell lymphoma as shown by increased levels of LC3B in MJ (from patients with mycosis fungoides) and Hut78 (from a patient with Sézary syndrome) cells ([@B153]).

### Perifosine {#s5_2_2}

The second generation APC, perifosine, activates autophagy by inhibiting Akt and the assembly of mTOR raptor and mTOR/rictor complexes and also by increasing degradation of the major components (mTOR, rictor, raptor, p70S6K, and 4E-BP1) in the mTOR axis through an ubiquitin/proteasome-mediated mechanism in human lung cancer cells (Fu et al., 2009). Combination of perifosine with other autophagy modulators may provide benefits in cancer regimens as shown by preclinical studies ([@B29]; [@B137]). Perifosine-induced autophagy may be protective and induces resistance against its cytotoxic and apoptotic effects which can be restored by addition of an autophagy inhibitor CQ in human chronic myelogenous leukemia cells ([@B137]). Perifosine can augment the autophagy induced by the mTOR inhibitor sirolimus and cause synergistic cytotoxicity in multiple myeloma cells; this mechanism may present a rationale for designing clinical trials in relapsed/refractory multiple myeloma ([@B29]). Perifosine and also the ether lipid edelfosine can induce autophagy by evoking an ER stress response, as demonstrated by a two- to threefold increased expression of the apoptotic transcription factor CHOP (C/EBP homologous protein)/GADD153 (growth arrest and DNA damage inducible gene 153) in human hepatoblastoma HepG2 cells, but not in human glioblastoma U-87 MG cells. It should be noted that miltefosine was devoid of this ER stress inducing effect ([@B123]), but erufosine was able to strongly cause ER stress (([@B5]) and see below).

A recent study revealed the potential role of APCs against neurodegenerative diseases. Enhancement of autophagy by perifosine may combat against TNF-α induced Akt/mTOR signaling, which promotes microglia polarization toward the neurotoxic M1 phenotype and inflammation ([@B65]).

### Erufosine {#s5_2_3}

APC induced autophagy is indicated by increased levels of the autophagic marker LC3B. Kapoor et al. ([@B70]) were the first to demonstrate that erufosine can cause both, apoptosis and autophagy, by affecting the Akt--mTOR signaling pathway ([@B71]). Exposure of oral squamous carcinoma cells to erufosine induced formation of acidic vesicular organelles as tested by acridine orange stain. Erufosine increased the ratio of lipidated LC3B-II to LC3B-I, denoting autophagosome formation in oral squamous carcinoma cells when compared to untreated controls. This effect probably results from the capability of the drug to inhibit the PI3K/Akt/mTOR pathway as a regulator of the autophagy process ([@B70]). The treated tumor cells showed reduced size, detached growth, and membrane blebbing as main characteristics of apoptosis ([@B70]; [@B71]).

In pancreatic ductal adenocarcinoma cells, erufosine showed also a dose-dependent increase in LC3B expression at mRNA and protein levels. Moreover, it caused an increased expression of the autophagy receptor optineurin in Suit2-007 cells ([@B2]).

Furthermore, erufosine induces endoplasmic reticulum and mitochondrial stress, which is linked to its effects on autophagy, apoptosis, and ROS induction. The association between erufosine and ER stress was shown by silencing and drug-induced inhibition of the ER stress sensors PERK and XBP1, which diminished the cellular effects of erufosine towards e.g. inhibition of proliferation, induction of apoptosis and autophagy ([@B5]).

Conclusion {#s6}
==========

In conclusion, autophagy is a multistep process, which can either suppress or favor cancer development. There are four subtypes, which have been named chaperone mediated autophagy, microautophagy, macroautophagy, and selective autophagy. Among other stimuli, autophagy is triggered by the complex 1 of mTOR, which, following its activation, inhibits autophagy induction. Alkylphosphocholine derivatives represent a membrane seeking class of antineoplastic agents that induce autophagy by inhibiting the Akt/mTOR cascade. They primarily interfere with phospholipid turnover and thus modify signaling chains, which start from the cell membrane and modulate PI3K/Akt/mTOR, Ras-Raf-MAPK/ERK and SAPK/JNK pathways. APCs include miltefosine, perifosine and erufosine, which represent the first-, second- and third generations of this class, respectively.

APCs inhibit Akt which acts as the main regulator of cell survival. In human cancers, the autophagic process is usually suppressed *in vitro* and *in vivo* by the constitutively active Akt and its downstream target mTOR. Therefore, exposure to APC derivatives, administered as monotherapy or in combination with other drugs, increases autophagy by reducing Akt/mTOR phosphorylation. Autophagy is a double-edged sword and may result in chemotherapeutic resistance as well as cancer cell death when apoptotic pathways are inactive. APCs display differential autophagy induction capabilities in different cancer cell types. Therefore, autophagy-dependent cellular responses need to be well understood in order to improve the chemotherapeutic outcome.
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